Daniel Levine

About Daniel Levine

DSL MUG-10-010Daniel S. Levine is an award-winning business journalist who has reported on the life sciences, economic development, and business policy issues throughout his 25-year career. He founded Levine Media Group in 2013, which produces The Bio Report and RARECast podcasts. Levine most recently served as managing director of publications for Burrill & Company, a global financial services firm focused exclusively on the life sciences. There he headed corporate communications, served as editor of The Burrill Report, a monthly digital publication focused on the business of the life sciences, and hosted the publication’s weekly podcast. Since 2011, he’s served as the lead editor and writer of Burrill & Company’s acclaimed annual book on the biotech industry. His work with Burrill & Company began through the firm’s joint venture magazine startup The Journal of Life Sciences, where he led the creation of the publication’s website and served as web editor before advancing to editor.

Prior to joining Burrill & Company, Levine worked as special projects editor for the San Francisco Business Times where he won numerous awards for his coverage of the biotechnology industry. His work has appeared in The New York Times, The Industry Standard, TheStreet.com, and other national publications. He is also the founder of the online magazine Disgruntled: The Business Magazine for People who Work for a Living and author of Disgruntled: The Darker Side of the World of Work (Berkley/Boulevard). Prior to that, he served as the San Francisco bureau chief for Adweek magazine. His coverage of the biotechnology industry began at the start of his journalism career while a business reporter at The Oakland Tribune. Before entering journalism, Levine spent five years in the investment banking industry and served as a vice president and general principal of Herbert Young Securities in Great Neck, New York. He holds a bachelor’s in English from Vassar College and a master’s in journalism from the University of California, Berkeley.

RARECast: Summit Pursues A Different Approach to Treating Duchenne
  Duchenne Muscular Dystrophy, a rare genetic disease, causes progressive muscle wasting that slowly robs people of their abilities and… Continue Reading
RARECast: Delivering Enzyme Replacement Therapies Across the Blood-Brain Barrier
Enzyme replacement therapies are available for a number rare, metabolic diseases that collectively are known as lysosomal storage disorders.… Continue Reading
RARECast: Sangamo Advances Gene Therapies for Multiple Rare Diseases Into Clinical Development
The promise of gene therapy has rare disease patients not only contemplating the potential of new treatments, but ones that can free them… Continue Reading
RARECast: Navigating the Challenges of Rare Disease Drug Development
  Clinical trials for rare disease therapies face many challenges. Some of these include the small patient population on which they draw,… Continue Reading
RARECast: How Rare Disease Patients Can Get their Voices Heard in Drug Discovery and Development
  There is increasing recognition of the important role patients can play by providing their insights into the drug discovery and… Continue Reading
RARECast: One Patient’s Difficult Road to a Rare Diagnosis
Porphyria is a rare and intensely painful blood disease. Because it can manifest itself with symptoms similar to those caused by far more… Continue Reading
RARECast: How Researchers Diagnosed Four Patients with a Never-Before-Identified Rare Disease in a Day
  Diagnosing a rare disease can take years. When it’s a disease that’s never been identified before, the search for a diagnosis can be… Continue Reading